NeoGenomics, Inc. (NEO) fair value analysis
Nasdaq · Updated 2026-10-19
NEO price how computed
Valuation status
Awaiting full valuationNEO's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once NEO's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $16.65
- Sector
- Healthcare
- 12-month range
- $7.19–$19.91
- Market cap
- $2.14B
- From 52-week high
- -16.4%
- Shares outstanding
- 128M
- Rank in Healthcare by quality score
- #128 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
NeoGenomics, Inc. is a clinical laboratory company that provides genomic testing services, including cancer diagnostics and other molecular testing for oncology and inherited conditions. The company operates testing facilities in the United States and serves healthcare providers and patients across the country.
NEO currently ranks #128 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $2.14B
- P/E (trailing)
- 185x
- Revenue (TTM)
- $766M
- Net margin
- -6.8%
- EPS (TTM)
- $0.09
- Gross margin
- 45.6%
- Debt / equity
- 0.57
- Revenue growth (3-yr avg)
- 10.9%
- Shares outstanding
- 128M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 37 · neutral
- 50-day average
- $17.55
- 200-day average
- $12.56
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-10-28 (post-market)
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+83.3%)
2026-03 ▼ miss (-12.3%)
2025-12 ▲ beat (+50.0%)
2025-09 ▲ beat (+50.0%)
2025-06 ▲ beat (+50.0%)
2025-03 ▼ miss (-1935.0%)
2024-12 ▲ beat (+39.9%)
2024-09 ▼ miss (-1494.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 4 hold · 0 sell (12 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $21.9
- Target vs last price
- +31.5%
What our data shows for NEO
- Our model validated 1 trailing price-to-earnings windows for NEO, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $7.19–$19.91.
- The 14-day relative strength index sits at a neutral 37.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- NEO's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent NEO news
TickrTrends' derived news-sentiment signal for NEO is currently leaning positive, computed from recent coverage.
- NeoGenomics (NEO) Expands AI-Driven Digital Pathology Collaboration with Indica Labs (gurufocus.com, 2026-10-15)
- NeoGenomics (NEO) Shares Plunge Over 12% Following Leadership Changes and Q3 Revenue Beat (gurufocus.com, 2026-10-06)
- NEO Maintained by StoneX -- Price Target Raised to $20 (gurufocus.com, 2026-10-06)
More NEO news
- NEO Maintained by Needham -- Price Target Raised to $22 (gurufocus.com, 2026-10-06)
What people are saying
Follow the NEO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for NEO show a shift in momentum this week as the 50/200-day trend state has moved from an uptrend to a mixed pattern, suggesting less directional clarity in recent price action. Additionally, the quality grade has declined from C to D, indicating a weakening in the underlying fundamental or technical metrics tracked by the indicator system. The stock's valuation verdict remains under review pending completion of a full valuation assessment.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for NEO show that the RSI zone has shifted from overbought to neutral since last week. The current valuation verdict remains awaiting full valuation. These changes reflect movements in the technical momentum metrics tracked for this healthcare sector stock over the past seven days.
- 2026-09-21 — TickrTrends' derived indicators for NEO in the Healthcare sector have shifted this week, with the relative strength index moving from neutral territory into overbought conditions. The company's current valuation verdict remains under review as full valuation analysis is awaited.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is NEO stock undervalued?
NEO's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is NEO's TickrTrends verdict?
NEO is currently marked 'Awaiting full valuation' - a verdict publishes automatically once NEO's own trailing P/E history validates under our standards.
How does NEO compare to other Healthcare stocks?
NEO ranks #128 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is NEO overbought or oversold?
NEO's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does NEO report earnings next?
NEO's next earnings report is scheduled for 2026-10-28 (post-market), per the published earnings calendar.
Does NEO usually beat earnings estimates?
Over its last 8 reported quarters NEO beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about NEO?
Of 12 analysts covering NEO, 8 rate it a buy, 4 a hold and 0 a sell - buy-leaning, with a consensus price target of $21.9 (+31.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.